Table 3 Incidence of treatment-related adverse events in 120 patients with advanced hepatocellular carcinoma who underwent pembrolizumab or nivolumab
From: Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Adverse event | Pembrolizumab (n = 25) |  | Nivolumab (n = 95) | P value | ||
|---|---|---|---|---|---|---|
Any grades | Grade 3/4 | Â | Any grades | Grade 3/4 | ||
Pruritis | 1 (4.0%) | 0 (0%) | Â | 4 (4.2%) | 0 (0%) | 0.96 |
Rash | 2 (8.0%) | 0 (0%) | Â | 8 (8.4%) | 0 (0%) | 0.95 |
Fatigue | 3 (12.0%) | 0 (0%) | Â | 10 (10.5%) | 0 (0%) | 0.83 |
Nausea | 1 (4.0%) | 0 (0%) | Â | 2 (2.1%) | 0 (0%) | 0.59 |
Diarrhea | 1 (4.0%) | 0 (0%) | Â | 4 (4.2%) | 0 (0%) | 0.96 |
Decreased body weight | 1 (4.0%) | 0 (0%) | Â | 2 (2.1%) | 0 (0%) | 0.59 |
Decreased appetite | 1 (4.0%) | 0 (0%) | Â | 3 (3.2%) | 0 (0%) | 0.84 |
Aspartate/Alanine aminotransferase increase | 2 (8.0%) | 0 (0%) | Â | 7 (7.4%) | 0 (0%) | 0.92 |
Hyperthyroidism | 0 (0%) | 0 (0%) | Â | 1 (1.1%) | 0 (0%) | 0.61 |
Hypothyroidism | 1 (4.0%) | 0 (0%) | Â | 3 (3.2%) | 0 (0%) | 0.84 |
Pneumonitis | 0 (0%) | 0 (0%) | Â | 0 (0%) | 0 (0%) | 1.0 |
Hypersensitivity/infusion-related reaction | 1 (4.0%) | 0 (0%) | Â | 2 (2.1%) | 0 (0%) | 0.59 |